GlaxoSmithKline Pharmaceuticals Limited (GLAXO.BO)

INR 2306.25

(-1.23%)

EBITDA Summary of GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited's latest annual EBITDA in 2023 was 8.87 Billion INR , up 4.71% from previous year.
GlaxoSmithKline Pharmaceuticals Limited's latest quarterly EBITDA in 2024 Q2 was 3.6 Billion INR , up 35.6% from previous quarter.
GlaxoSmithKline Pharmaceuticals Limited reported an annual EBITDA of 9.03 Billion INR in 2022, up 4.47% from previous year.
GlaxoSmithKline Pharmaceuticals Limited reported an annual EBITDA of 8.48 Billion INR in 2021, up 12.53% from previous year.
GlaxoSmithKline Pharmaceuticals Limited reported a quarterly EBITDA of 2.3 Billion INR for 2024 Q1, down -8.05% from previous quarter.
GlaxoSmithKline Pharmaceuticals Limited reported a quarterly EBITDA of 2.57 Billion INR for 2023 Q4, up 4.51% from previous quarter.

Annual EBITDA Chart of GlaxoSmithKline Pharmaceuticals Limited (2023 - 2004)

Historical Annual EBITDA of GlaxoSmithKline Pharmaceuticals Limited (2023 - 2004)

Year	EBITDA	EBITDA Growth
2023	8.87 Billion INR	4.71%
2022	9.03 Billion INR	4.47%
2021	8.48 Billion INR	12.53%
2020	5.35 Billion INR	18.93%
2019	3.92 Billion INR	-10.9%
2018	7.31 Billion INR	24.69%
2017	5.77 Billion INR	14.43%
2016	4.91 Billion INR	-18.15%
2015	4.87 Billion INR	18.08%
2014	5.08 Billion INR	-27.85%
2013	7.31 Billion INR	-28.54%
2012	8.52 Billion INR	3.97%
2011	9.54 Billion INR	4.68%
2010	9.06 Billion INR	17.76%
2009	7.7 Billion INR	30.72%
2008	5.89 Billion INR	17.18%
2007	5.02 Billion INR	24.87%
2006	4.02 Billion INR	28.65%
2005	3.12 Billion INR	-18.19%
2004	3.82 Billion INR	0.0%

Year	EBITDA	EBITDA Growth
2024 Q2	3.6 Billion INR	35.6%
2024 Q1	2.3 Billion INR	-8.05%
2023 Q4	2.57 Billion INR	4.51%
2023 Q2	3.17 Billion INR	76.19%
2023 Q3	2.46 Billion INR	-22.51%
2023 FY	- INR	4.71%
2023 Q1	1.8 Billion INR	8.24%
2022 FY	- INR	4.47%
2022 Q1	1.76 Billion INR	-8.84%
2022 Q2	2.78 Billion INR	57.99%
2022 Q3	2.52 Billion INR	-9.6%
2022 Q4	1.66 Billion INR	-33.92%
2021 Q3	2.08 Billion INR	-23.23%
2021 Q2	2.71 Billion INR	64.85%
2021 Q4	1.93 Billion INR	-6.96%
2021 FY	- INR	12.53%
2021 Q1	1.64 Billion INR	-30.13%
2020 Q3	2.03 Billion INR	-4.81%
2020 Q2	2.13 Billion INR	24.37%
2020 Q1	1.71 Billion INR	117.83%
2020 FY	- INR	18.93%
2020 Q4	2.35 Billion INR	15.59%
2019 Q4	789.57 Million INR	-43.96%
2019 FY	- INR	-10.9%
2019 Q3	1.4 Billion INR	-32.87%
2019 Q2	2.09 Billion INR	7.03%
2019 Q1	1.96 Billion INR	-8.49%
2018 Q3	1.53 Billion INR	-14.61%
2018 FY	- INR	24.69%
2018 Q4	2.14 Billion INR	39.39%
2018 Q2	1.8 Billion INR	17.18%
2018 Q1	1.53 Billion INR	0.0%
2017 Q1	334.3 Million INR	0.0%
2017 FY	- INR	14.43%
2016 FY	- INR	-18.15%
2015 FY	- INR	18.08%
2014 FY	- INR	-27.85%
2013 FY	- INR	-28.54%
2012 FY	- INR	3.97%
2011 FY	- INR	4.68%
2010 FY	- INR	17.76%
2009 FY	- INR	30.72%
2008 FY	- INR	17.18%
2007 FY	- INR	24.87%
2006 FY	- INR	28.65%
2005 FY	- INR	-18.19%
2004 FY	- INR	0.0%

Peer EBITDA Comparison of GlaxoSmithKline Pharmaceuticals Limited

Name	EBITDA	EBITDA Difference
Abbott India Limited	16.97 Billion INR	47.738%
Cipla Limited	67.19 Billion INR	86.795%
Gland Pharma Limited	15.03 Billion INR	40.977%
Kopran Limited	890.24 Million INR	-896.69%
Marksans Pharma Limited	4.58 Billion INR	-93.49%
NGL Fine-Chem Limited	678.68 Million INR	-1207.377%
Pfizer Limited	8.23 Billion INR	-7.711%
Sanofi India Limited	8.86 Billion INR	-0.056%
SMS Pharmaceuticals Limited	1.21 Billion INR	-632.824%